Immunotherapies and novel combinations: the focus of advances in the treatment of melanoma

Cancer Immunology, Immunotherapy

Volumn 64, Issue 3, 2015, Pages 271-274

  Ascierto, Paolo A ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Combination strategies; Immunotherapy; Ipilimumab; Melanoma; Nivolumab; Pembrolizumab

Indexed keywords

ANTINEOPLASTIC AGENT; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; VEMURAFENIB; MONOCLONAL ANTIBODY;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOTHERAPY; METASTATIC MELANOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; IMMUNOLOGY; MELANOMA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MELANOMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84924055386     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1647-3     Document Type: Article

References (11)

1. Weber J, Minor D, D’Angelo S, Hodi FS, Gutzmer R, Neyns B et al (2014) A phase 3 randomized, open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator’s choice chemotherapy (ICC) in patients with advanced melanoma after prior anti-CTLA-4 therapy. ESMO Abstract LBA3_PR
2. Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412–7420
3. McDermott D, Kluger H, Sznol M, Carvajal R, Lawrence D, Topalian SL et al (2014) Long-term survival of ipilimumab-naïve patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in a phase 1 trial. ESMO Abstract 1088PD
4. Robert C, Joshua A, Weber J, Ribas A, Hodi FS, Kefford R et al (2014) Pembrolizumab (pembro; MK-3475) for advanced melanoma (MEL): Randomized comparison of two dosing schedules. ESMO Abstract LBA34
5. Ribas A, Hodi FS, Kefford R, Hamid O, Daud A, Wolchok JD et al (2014) Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). J Clin Oncol 32(5s):LBA9000
6. Eggermont AM, Chiarion-Sileni V, Grob J, Dummer R, Wolchok J, Schmidt H et al (2014) Efficacy, safety, and quality of life (QoL) data from the EORTC 18071 phase III trial of ipilimumab (Ipi) versus placebo after complete resection of stage III melanoma. ESMO Abstract 1087O
7. Kluger H, Sznol M, Calllahan M, Postow M, Gordon R, Segal NH et al (2014) Survival, response duration, and activity by BRAF mutation (MT) status in a phase 1 trial of nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). ESMO Abstract 1085O
8. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J et al (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367:1694–1703
9. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J et al (2014) Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 371:1877–1888
10. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewitz A, Stroyakovskiy D et al (2014) COMBI-v: A randomised, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (V) as first-line therapy in patients with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. ESMO Abstract LBA4_PR
11. Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M et al (2014) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371:1867–1876